Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2163 • 2019 ACR/ARP Annual Meeting
Prevalence of Postoperative Anemia in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Undergoing Total Knee Arthroplasty: A Study of National Inpatient Sample 2010-2014
Karan Jatwani ¹, Karan Chugh ², Bikramjit Bindra ³ and Shraddha Jatwani², ¹Mount Sinai West - St Luke’s Hospital, New York, ²St. Vincent Evansville, Evansville, ³Government Medical College & Hospital, Chandigarh, India
Background/Purpose: Total knee arthroplasty (TKA) is a valuable option for improving function and pain control in patients with end-stage arthritis, especially those with inflammatory arthritis…
Abstract Number: 2302 • 2019 ACR/ARP Annual Meeting
Comparison Between Fibromyalgia and Neuropathic Pain in Patients with Established Rheumatoid Arthritis
Yong Gil Hwang¹, Lei Zhu ¹ and Larry Moreland ¹, ¹University of Pittsburgh, PITTSBURGH, PA
Background/Purpose: Our objectives were (1) to identify similarities and differences of pain symptoms identified by fibromyalgia (FM) and neuropathic pain (NP) screening tool (2) to…
Abstract Number: 2323 • 2019 ACR/ARP Annual Meeting
The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Sicong Huang ¹, Zeling He ¹, Daniel Solomon ², Elena Massarotti ³, Charlotte Golnik ¹, Thany Seyok ¹, Seth Brownmiller ⁴, Tianrun Cai ³, Nicole Yang ³, Laurel Campbell ³, Leanne Barrett ³, Courtney Bibbo ³, Kenneth Pariser ³, Derrick Todd ³, Marcy Bolster ⁴, Marcelo Di Carli ³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: Inflammation accounts for much of the excess cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). We hypothesize that increased systemic inflammation leads to…
Abstract Number: 2342 • 2019 ACR/ARP Annual Meeting
Association of Serum KL-6 Level and Change of Pulmonary Function in Interstitial Lung Disease of Rheumatoid Arthritis – Data from Prospective KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) Study
Jeong Seok Lee¹, Young Im Yoon ², Eun Young Lee ³, Jung Yoon Choe ⁴, Hwa Jung Lee ⁵, Yong-Beom Park ⁶, Eun Ha Kang ⁷, You-Jung Ha ⁷, Yeon-Ah Lee ⁸ and Seong Hye Jang ⁹, ¹Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ⁴Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, Republic of Korea, ⁵DAEGU CATHOLIC UNIVERSITY, Daegu, Republic of Korea, ⁶Yonsei university college of medicine, severance hospital, Seodaemun-gu, Seoul-t'ukpyolsi, Republic of Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁸School of Medicine, Kyung Hee University, Seoul, Republic of Korea, ⁹Soonchunhyang University, Cheonan, Republic of Korea
Background/Purpose: Interstitial lung disease (ILD) is the most common lung disease among rheumatoid arthritis (RA) patients. Although the overall mortality rates for RA have decreased…
Abstract Number: 2368 • 2019 ACR/ARP Annual Meeting
Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study
Claire Rempenault¹, Cédric Lukas ¹, Bernard Combe ², Isabelle Pane ³, Xavier Mariette ⁴, Jacques-Eric Gottenberg ⁵ and Jacques Morel ¹, ¹Department of Rheumatology, Montpellier University Hospital, Montpellier, France, Montpellier, Languedoc-Roussillon, France, ²CHU Montpellier, Montpellier University, Montpellier, France, ³Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris, France., Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Several studies have reported an increased risk of gastro-intestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) compared to conventional synthetic…
Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting
Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…
Abstract Number: 2805 • 2019 ACR/ARP Annual Meeting
Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls
Noha Elemam¹, Mahmood Hachim ¹, Suad Hannawi ² and Azzam Maghazachi ¹, ¹Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, Sharjah, United Arab Emirates, ²Ministry of Health and Prevention-UAE, Department of Rheumatology, Dubai, United Arab Emirates
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune diseases (1-3% of the world’s population). RA is a prototypic inflammatory disease, being characterized by an…
Abstract Number: 2906 • 2019 ACR/ARP Annual Meeting
DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Elise van Mulligen¹, Angelique Weel ², Martijn Kuijper ², Mieke Hazes ¹, Annette van der Helm-van Mil ³ and Pascal de Jong ¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: In rheumatoid arthritis (RA) disease outcomes have improved enormously in the last decades. Due to early initiation of therapy, a treat-to-target approach and a…
Abstract Number: 2823 • 2019 ACR/ARP Annual Meeting
Progression to Inflammatory Arthritis After Screening Autoantibody Positive in a Non-Clinical Setting
Jill Norris¹, Elizabeth Bemis ², Marie Feser ³, M. Kristen Demoruelle ⁴, Jennifer Seifert ⁵, Michael Weisman ⁶, Jane Buckner ⁷, Peter Gregersen ⁸, Ted Mikuls ⁹, James O'Dell ⁹, Richard M. Keating ¹⁰, Kevin Deane ³ and V. Michael Holers ⁵, ¹Colorado School of Public Health, Aurora, ²University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, ⁵University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Benaroya Research Institute, Seattle, WA, ⁸Feinstein Institutes for Medical Research, Manhasset, NY, ⁹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ¹⁰Scrippshealth, La Jolla
Background/Purpose: Rheumatoid arthritis (RA)-related autoantibodies are typically elevated prior to the onset of seropositive RA. Screening for autoantibody (aAb) positive individuals is a means to…
Abstract Number: 41 • 2019 ACR/ARP Annual Meeting
Liver Dysfunction Associated with Rheumatoid Arthritis: Impact of Obesity and Effects of DMARDs in Hepatic Alterations
Ivan Arias de la Rosa¹, Carmen Torres-Granados ¹, Alejandro Ibañez-Costa ², Maria del Carmen Abalos-Aguilera ², Alejandra Patiño-Trives ², Maria Luque-Tevar ², Carlos Perez-Sanchez ³, Jose Cordoba-Chacon ⁴, Rafaela Ortega ², Jerusalem Calvo-Gutierrez ², Eduardo Collantes-Estevez ¹, Alejandro Escudero ⁵, Chary Lopez-Pedrera ² and Nuria Barbarroja ⁶, ¹University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁴Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, University of Illinois, Chicago, USA, Chicago, IL, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain
Background/Purpose: 1) To analyze the impact of rheumatoid arthritis (RA) in the liver function, 2) To evaluate the impact of obesity and the effect of…
Abstract Number: 176 • 2019 ACR/ARP Annual Meeting
The Epidemiology of Rheumatoid Arthritis in the Czech Republic
Jakub Závada¹, Monika Bezděková ², Michal Uher ³ and Jiří Jarkovský ⁴, ¹Institute of Rheumatology, Prague, Prague, Czech Republic, ²Institute of Health Information and Statistics of the Czech Republic, Praha, Hlavni mesto Praha, Czech Republic, ³Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic, ⁴Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Praha, Hlavni mesto Praha, Czech Republic
Background/Purpose: To describe the epidemiology of Rheumatoid Arthritis (RA) in the Czech Republic (CZ)Methods: We used the administrative database of the National Registry of Reimbursed…
Abstract Number: 209 • 2019 ACR/ARP Annual Meeting
Joint Overuse in Patients with Rheumatoid Arthritis
Daisuke Kobayashi¹, Sachimi Amao ², Satoshi Ito ³, Kiyoshi Nakazono ³, Hajime Ishikawa ⁴ and Ichiei Narita ¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ²Nursing department, Niigata Rheumatic Center, Shibata, Japan, ³Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ⁴Department of Rheumatology, Niigata Rheumatic Center, Shibata, Niigata, Japan
Background/Purpose: The development of drug therapies for rheumatoid arthritis (RA), and control of synovitis has now become easier. However, once patients are relieved of pain,…
Abstract Number: 417 • 2019 ACR/ARP Annual Meeting
Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis
Mart A.F.J. van de Laar¹, Janet Pope ², Yvonne Lee ³, Bruno Fautrel ⁴, Kei Ikeda ⁵, Amanda Quebe ⁶, Xiang Zhang ⁶, Carol Gaich ⁶, Francesco De Leonardis ⁶, Jeffrey Lisse ⁶, Jennifer Workman ⁶, Roy Fleischmann ⁷, Mark Genovese ⁸ and Peter Taylor ⁹, ¹Arthritis Center Twente, Enschede, Netherlands, ²Western University, London, ON, Canada, ³Northwestern University Feinberg School of Medicine, Chicago, ⁴Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁵Chiba University Hospital, Chiba, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁸Stanford University, Stanford, CA, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, has shown clinical efficacy and patient-reported pain relief in patients (pts) with RA and…
Abstract Number: 459 • 2019 ACR/ARP Annual Meeting
The Effects of Erythrocytes and Platelets on Disease Activity in Patients with RA – ANSWER Longitudinal Cohort Study –
Akira Onishi¹, Kengo Akashi ¹, Sadao Jinno ², Yonsu Son ³, Hideki Amuro ³, Toru Hirano ⁴, Yuichi Maeda ⁵, Motomu Hashimoto ⁶, Wataru Yamamoto ⁶, Kosaku Murakami ⁶, Ryota Hara ⁷, Masanori Katayama ⁸, Tohru Takeuchi ⁹, Takuya Kotani ⁹, Jun Saegusa ¹ and Akio Morinobu ¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ³First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ⁴Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan, ⁵Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁶Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁷The Center for Rheumatic Disease, Department of Orthopedic Surgery, Nara Medical University, Nara, Japan, ⁸Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁹Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan
Background/Purpose: Experimental models suggested both erythrocytes and platelets activated immune cells and enhanced inflammation in inflammatory arthritis. Although previous cross-sectional studies showed the form and…
Abstract Number: 497 • 2019 ACR/ARP Annual Meeting
Women with Rheumatoid Arthritis Have Higher Lifetime Occupational and Non-occupational Exposure to Silica Dust Compared to French General Population
Johanna Sigaux¹, Catherine Cavalin ², Odile Macchi ², Salima Challal ³, Mylene Petit ⁴, Patrice Decker ⁵, Emma André ⁴, Paul-André rosental ², Marie-Christophe Boissier ⁶ and Luca Semerano ⁷, ¹INSERM UMR 1125, Université Paris 13, Bobigny, France, ²SILICOSIS project, ERC Advanced Grant, Centre for European Studies, Sciences Po, Paris, France, Paris, France, ³Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne Service de Rhumatologie, Bobigny, France, ⁴INSERM UMR 1125 Sorbonne Paris Cité, Université Paris 13, 93000 Bobigny, France, Paris, France, ⁵Inserm UMR 1125, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ⁶Assistance Publique-Hôpitaux de Paris (AP-HP), Rheumatology Department, Avicenne Hospital, Bobigny, France, ⁷INSERM UMR 1125 , Université Paris 13, Bobigny, France
Background/Purpose: Occupational exposure to silica dust is a well-known risk factor for ACPA positive rheumatoid arthritis (RA). The role of non-occupational exposure has not been…

« Previous Page
1
…
7
8
9
10
11
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].